Arrowhead partners two programs with Amgen
Arrowhead Pharmaceuticals Inc. is partnering two of its RNA interference (RNAi) cardiovascular disease therapies with Amgen Inc.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.